BOTHELL, Wash., July 31, 2017 /PRNewswire/ -- BioLife
Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer
and marketer of proprietary clinical grade cell and tissue
hypothermic storage and cryopreservation freeze media ("BioLife" or
the "Company"), today announced that it has executed a long term
supply agreement with NASDAQ-listed Celyad, a leader in the
discovery and development of CAR-T cell therapies. BioLife's
CryoStor clinical grade cell freeze media is incorporated into
Celyad's manufacturing process for its Natural Killer Receptor
based T-Cell (NKR-T) platform.
In addition, CryoStor and HypoThermosol®, BioLife's
companion cell storage and shipping media, have been used in at
least 250 regenerative medicine applications, including several
late stage clinical trials.
Mike Rice, BioLife President
& CEO, commented, "The execution of this new supply agreement
further validates the critical role our proprietary biopreservation
media products play in the development and commercialization of
cellular therapies. We are very pleased to support Celyad in their
mission to bring potential life-saving cell-based products to the
market."
About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on
the development of specialized CAR-T cell based therapies. The
company utilizes its expertise in cell engineering to target
cancer. Celyad's Natural Killer Receptor based T-Cell (NKR-T)
platform has the potential to treat a broad range of solid and
hematologic tumors. Its lead oncology candidate, CYAD-01
(CAR-T NKG2D), is being evaluated in the THINK open-label
Phase I study to assess the safety & clinical activity of
multiple administrations of autologous CAR-T NKR-2 cells in 7
refractory cancers. Celyad is also advancing a robust
immuno-oncology pipeline that includes CYAD-02 (Celyad's allogeneic
platform), CYAD-03 (CAR-T B7H6), CYAD-04 (CAR-T NKp30) and CYAD-05
(CAR-T NKG2Dβ), all at pre-clinical stage. Celyad was founded in
2007 and is based in Mont-Saint-Guibert, Belgium, and Boston,
Massachusetts. Celyad's ordinary shares are listed on the
Euronext Brussels and Euronext Paris exchanges, and its American
Depository Shares are listed on NASDAQ Global Market, all under the
ticker symbol CYAD.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets
biopreservation media products and smart shipping containers
connected to a cloud hosted cold chain management app to improve
the quality of delivery logistics for cells, tissues, and organs.
The Company's proprietary HypoThermosol® and
CryoStor® platform of solutions are highly valued in the
biobanking, drug discovery, and regenerative medicine markets.
BioLife's biopreservation media products are serum-free and
protein-free, fully defined, and are formulated to reduce
preservation-induced cell damage and death. BioLife's enabling
technology provides commercial companies and clinical researchers
significant improvement in shelf life and post-preservation
viability and function of cells, tissues, and organs. For
more information please visit www.biolifesolutions.com, and follow
BioLife on Twitter.
This press release contains forward-looking statements,
including, but not limited to, statements concerning new products,
the company's anticipated business and operations, the potential
utility of and market for its products and services, potential
revenue growth and market expansion, and commercial manufacturing
of our customers' products. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking
statements, including among other things, uncertainty regarding
market adoption of products; uncertainty regarding third party
market projections; market volatility; competition; litigation; and
those other factors described in our risk factors set forth in our
filings with the Securities and Exchange Commission from time to
time, including our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. We undertake no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be
required by applicable law.
Media & Investor Relations
Roderick de Greef
Chief Financial Officer
(425) 686-6003
rdegreef@biolifesolutions.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-executes-supply-agreement-with-celyad-for-cryostor-use-in-natural-killer-receptor-based-t-cell-nkr-t-platform-targeting-solid-tumors-and-blood-cancers-300496245.html
SOURCE BioLife Solutions, Inc.